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ABSTRACT
URINARY PHTHALATE METABOLITE CONCENTRATIONS AND CANCER
MORTALITY IN NHANES, 1999-2006
MAY 2015
AMY BRADSHAW KAISER, B.A., MOUNT HOLYOKE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Professor Katherine Reeves

Four in ten people in the US will be diagnosed with cancer during their lifetime.
Environmental exposures are important determinants of cancer risk, causing as many as
19% of cancers worldwide. Phthalates are a group of chemicals used to increase the
flexibility of plastics and vinyl in household materials such as food packaging, plastic
toys, wood finishes and adhesives. Some phthalates may act as endocrine disruptors
with hypothesized links to endometriosis, breast cancer, and reproductive outcomes.
However, no research yet exists on phthalate exposure and all-cancer mortality. We
investigated the relationship between seven urinary phthalate metabolites among 5,205
adults in National Health and Nutrition Examination Survey (NHANES), from 1999 to
2006 with mortality data through 2011. Urinary phthalate metabolites were measured in
spot urine samples using HPLC-MS/MS and HPLC-ESI-MS/MS. Cox proportional
hazard regressions were conducted to calculate hazard ratios and 95 percent confidence
intervals for all-cancer mortality, stratified by gender. Mean creatinine adjusted
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metabolite concentrations ranged from 0.03 – 3.86 ug/mg in males and 0.07 – 4.37 ug/mg
in females. Age-adjusted and multivariate Cox proportional hazard models did not yield
statistically significant results for any metabolites. Hazard ratios in the multivariate
model for continuous, creatinine adjusted, log transformed metabolite concentrations,
ranged from 0.90 to 1.27 in men and 0.86 to 1.07 in women. There was no evidence for a
dose-response relationship in the quartile analyses, with p-values for trend above 0.12.
This research contributes to the limited cancer literature on phthalate exposure that helps
direct future regulations on plasticizers in consumer products.

v

TABLE OF CONTENTS
Page
ACKNOWLEGEMENTS……………………………………………………..…………iii
ABSTRACT………………………………………………………………………...……iv
LIST OF TABLES……………………………………………………………………….vii
CHAPTER
1. INTRODUCTION………………………………………………………………...……1
Physiology of Phthalate Cancer Relationship……………………………………..3
Epidemiology of Phthalate Cancer Relationship………………………………….3
Summary of Significance and Innovation…………………………………………5
2. METHODS……………………………………………………………………………..7
Study Design………………………………………………………………………7
Study Population………..…………………………………………………………7
Urinary Phthalate Metabolite Assessment………………………...........................8
Validation of Urinary Phthalate Metabolite Assessment………………………….9
Cancer Mortality Assessment…..............................................................................9
Validation of Cancer Mortality………………………………………………… 10
Covariate Assessment……………………………………………………………11
Data Analysis…………………………………………………………………….12
3. RESULTS……………………………………………………………………………..13
4. DISCUSSION…………………………………………………………………………15
5. CONCLUSION………………………………………………………………………..18
APPENDIX: TABLES…………………………………………………………………..19
BIBLIOGRAPHY……………………………………………………………………..…31

vi

LIST OF TABLES
Table

Page

1. Sources of exposure, metabolites and analytical data for assessed phthalates………..19
2. Number and percent in final study sample, NHANES 1999-2006……………………20
3. Distribution of covariates, NHANES 1999-2006……………………………………..21
4. Distribution of cancer mortality, NHANES 1999-2006
with follow-up through 2011…………………………………………………………….22
5. Distribution of creatinine adjusted, phthalate metabolite concentration (ug/mg),
NHANES 1999-2006…………………………………………………………………….22
6. Distribution of creatinine adjusted, log transformed phthalate metabolite concentration
(ug/mg) and coefficients, males, NHANES 1999-2006…………………………………23
6a. Distribution of creatinine adjusted, log transformed phthalate metabolite
concentration (ug/mg) and coefficients, males, NHANES 1999-2006 …………………24
7. Distribution of creatinine adjusted, log transformed phthalate metabolite concentration
(ug/mg) and coefficients, females, NHANES 1999-2006……………………………….25
7a. Distribution of creatinine adjusted, log transformed phthalate metabolite
concentration (ug/mg) and coefficients, females, NHANES 1999-2006 ……………….26
8. Adjusted hazard ratios and 95% confidence intervale for cancer mortality and
creatinine adjusted, log transformed urinary phthalate metabolite concentration (ug/mg),
males, NHANES 1999-2006……………………………………………………………27
9. Adjusted hazard ratios and 95% confidence intervale for cancer mortality and
creatinine adjusted, log transformed urinary phthalate metabolite concentration (ug/mg),
females, NHANES 1999-2006…………………………………………………………28

vii

CHAPTER 1
INTRODUCTION
In 2014, the rate of cancer in the US was 460.4 per 100,000 with an average 5year survival rate of 66.1 percent. Since 1992, the incidence and mortality rates of cancer
have been slowly decreasing, but it is still one of the most burdensome diseases in the
country. The three most common cancer sites are breast, lung, and colorectal, which
together account for about 40 percent of all new cancer cases.1 Risk factors for cancer
are extremely broad, and depend on the cancer site, and in some cases, the histological
type. In general, they include lifestyle factors, such as smoking, diet, alcohol, and
exercise; genetics; psychological stress; radiation and magnetic field exposure, including
CT scans, x-rays, radon; infectious agents such as human immunodeficiency virus,
Human papillomavirus, and H. pylori; and chemical or environmental exposures,
including asbestos, formaldehyde, some pesticides, and possibly bisphenol A and
phthalates.2
Phthalates are a family of chemicals ubiquitous in countless industrial products.
They hold color and fragrance and add gloss to personal care products; provide time
releasing for some pharmaceuticals; and most commonly, add flexibility to polyvinyl
chloride (PVC).3 Higher molecular weight phthalates, including di-(2-ethylhexyl)
phthalate (DEHP), di-isodecyl phthalate (DiBP), and di-isononyl pthalate (DiNP) are
most common in construction material, clothing, children’s toys, household furnishings,
and as a plasticizer in PVC. Lower molecular weight phthalates, dibutyl phthalates
(DBP), dimethyl phthalate (DMP), and diethyl phthalate (DEP), are typically used as
solvents in adhesives, pharmaceuticals, waxes, inks, and cosmetics (Table 1).4, 5

1

Humans have opportunity to be exposed to phthalates through ingestion,
inhalation, intravenous injection, and skin absorption. Phthalates are not covalently
bound to the PVC plastics, and tend to leach, migrate or evaporate into the environment.
3, 6

The most common route of exposure is ingestion (through food, medicine, or

children’s toys), inhalation (house dust and indoor air), intravenous (medical tubing), and
dermal absorption (direct contact with clothing, waxes, cleaning products, cosmetics).5
Medical devices are a particularly common source of exposure. Phthalates (particularly
DEHP) are used as softeners for medical tubing or medical bags used for administering
blood and nutritional formulas, as well as gases for respiratory treatments, and are in
medicine packaging and coatings of supplements and herbal treatments. Therefore,
individuals undergoing medical treatment have phthalate exposure associated with each
treatment (e.g. intravenous exposure to DEHP from a blood transfusion in a trauma
patient is about 8.5 mg/kg/day)5.
Phthalates are quickly metabolized in the body into monoesters, and then
depending on the phthalate, further metabolized into oxidative products of their lipophilic
aliphatic side chain, then excreted in urine and feces3. According to the National Health
and Nutrition Examination Survey (NHANES), several phthalate metabolites are
detectable in the urine of 97 percent of the total US population,7 and adult women have
particularly high levels of metabolites associated with phthalates used in cosmetics and
personal care products.8 Phthalates are suspected to act as endocrine disruptors in
humans, which may be associated with infertility, endometriosis, and some endocrine
related cancers, possibly by mimicking naturally occurring hormones, blocking
endogenous hormones from binding, or altering the production of hormones in the body.9
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The National Toxicology Project has classified one phthalate DEHP as Group 2B,
possibly carcinogenic to humans, based on sufficient evidence for carcinogenicity in
animal studies. 10
Physiology of PhthalateCancer Relationship
The carcinogenic mechanism for phthalates is unclear and the specific
carcinogenic mechanism and metabolism of endocrine disruptors is poorly understood.
Endocrine disrupters are typically considered compounds that bind to steroid hormone
receptors to mimic or block the transcriptional activation elicited by naturally circulating
steroid hormones. Hsieh et al. demonstrated that phthalates could induce proliferation,
migration, invasion, and tumor formation and initiate a cascade of events that facilitates
cancer, specifically ER-negative breast cancer.11
They can also act as hormone sensitizers by inhibiting histone deacetylase activity
and can stimulate mitogen-activated protein kinase activity. Additionally, they may have
effects on receptors other than ER, AR, and thyroid hormone receptor and can have
genome-wide effects on DNA methylation.12
Epidemiology of PhthalateCancer Relationship
The association between phthalate exposure and all cancer mortality has not been
previously been studied. However, three studies have examined breast cancer and
exposures to phthalates or endocrine disruptors, and one study examined lung cancer and
occupational exposures, including phthalates.
Two occupational case-control studies evaluated breast cancer. Aschengrau et al.
13

evaluated occupational exposure to 18 estrogenic chemicals assigned according to job

description, and risk of breast cancer among 261 employees compared to 753 population
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controls. Cases only exposed to butylbenzyl phthalate (BBzP) (n=4 cases) had an
adjusted odds ratio of 0.9 (95% CI: 0.3-2.9) compared to controls with the same
exposure. Combined exposure to BBzP phthalate and other xenoestrogens (defined as any
of 33 substances with estrogenic properties in E-SCREEN bioassay), had an adjusted OR
of 0.7 (95% CI: 0.4-1.2) compared to controls with the same exposure. Brophy et al. 2012
14

conducted compared occupational work history of 1,005 breast cancer cases with 1,146

community controls. They reported that women in jobs with high exposures to endocrine
disruptors had elevated breast cancer risk (OR=1.42, 95% CI: 1.18-1.73), with
particularly elevated risks among automotive plastics manufacturing (OR=2.68, 95% CI:
1.47-4.88).
A third occupational case-control study15 compared 43 cases that died of lung
cancer from 1976 to 1979 to community controls that died in the same time period. Cases
were more likely to work in a plant that produced phthalates (OR=5.2), but the plant also
produced large levels of soot. The analysis adjusted for age and smoking, but not soot
exposures.
These studies are limited by misclassification of exposure and lack of individual
exposure. Since exposure assessment was based on work history, it is not clear exactly
which chemicals are responsible for the increased risk. Especially in cases where
participants held multiple jobs over a lifetime, results could be confounded by other
occupational exposures. Records-based occupational studies also may not have
comprehensive, reliable covariate data which introduces unadjusted confounding or
residual confounding. There could also be recall bias, typical of case-control studies, or
chance findings.
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Lopez Carrillo et al.16 conducted a case-control study of breast cancer, with 233
cases and 221 age-matched controls, and assessed phthalate exposure through urine
metabolites. For the sum of all metabolites, the authors reported slightly increased odds
of breast cancer in the third tertile compared to the first tertile, which was not statistically
significant (OR=1.09, 95% CI=0.69-1.71). They also reported statistically significant
increased odds of breast cancer in the third tertile compared to the first tertile in some
metabolites: DEP metabolites, OR=2.20, 95% CI=1.33-3.63; DEHP metabolites,
OR=1.68, 95% CI=1.01-2.78. However, they also found statistically significant
protective effects when comparing the third tertile to the first: BBzP metabolites,
OR=0.46, 95% CI=0.27-0.79; DOP metabolites, OR=0.44, 95% CI: 0.24-0.80. These
results demonstrate the importance of assessing individual compounds, since each
phthalate does not affect risks of breast cancer equally; this study found that most either
have no effect or a protective effect on risk. Additionally, the effect sizes in this study
may be overestimated because phthalates are found in medical equipment and
medications. Therefore, cases will have higher exposure to phthalates than controls due to
their cancer treatments, not because their exposure increased their risk of cancer.
Summary of Significance and Innovation
Given the high percentage of Americans exposed to phthalates on a daily basis,
further research on the health implications of these substances is increasingly important.
The existing literature suggests possible health implications of phthalates and the possible
carcinogenicity of endocrine disruptors. However, cancer incidence or mortality has not
been adequately assessed. This study is significant given the prevalence of phthalates in
consumer products, and its suspected carcinogenicity and is innovative by evaluating the
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association between urinary phthalate metabolites and cancer mortality in a large
population with a verified exposure assessment.
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CHAPTER 2
METHODS
Study Design
Using a prospective cohort design, we conducted a mortality analysis to assess the
association between urinary phthalate metabolites and all cancer mortality using four
National Health and Nutrition Examination Survey (NHANES) series from 1999-2006,
linked with mortality data through 2011. NHANES is a national survey from the National
Center for Health Statistics, part of the Center for Disease Control and Prevention (CDC).
The assessment included an interview component to collect sociodemographic, household
and medical information; as well as a mobile examination component (MEC) for blood
and urine samples which was conducted for a random sample of one third of the
participants. The NHANES interview team included physicians, medical technicians and
health interviewers. The interviews were conducted in the participants’ houses, and the
MECs were conducted in mobile centers.17
Study Population
The NHANES survey is the longest ongoing survey of the US population. The
survey began in the 1960s, with the continuous series beginning in 1999. Each NHANES
series includes 2 years and enrolls about 10,000 participants each series. Participants are
randomly selected through a complex survey design, designed to be representative of
civilian, noninstitutionalized US population; African Americans, Mexican Americans,
infants, children, and the elderly were oversampled to ensure the sample was fully
representative. 17 The public-use linked mortality files provide linkage with the National
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Death Index (NDI) and Social Security Administration (SSA) databases for vital status
and cause of death data. Mortality data are available through December 31, 2011.18
NHANES surveyed about 41,400 participants over the four series. Participants
were eligible for our study if they were adults (more than 20 years old) who underwent
the MEC assessment and were randomly selected for the phthalate assessment of the
MEC assessment (n=5205, evenly distributed between each series)1. We further excluded
participants who died within 12 months of the MEC assessment (n=67), who were ever
diagnosed with a cancer other than melanoma (n=434), or who were pregnant at time of
MEC assessment (n=378), to eliminate confounding by prevalent cancers or conditions,
increased medicalization or changes in phthalate metabolism. We also excluded
participants who had incomplete mortality follow-up (n=8). Our final study population
included 5,205 participants (Table 2).
Urinary Phthalate Metabolite Assessment
Phthalate metabolites were measured on a random one-third sample of the MEC
assessment participants, starting in 1999. One spot urine sample was collected from each
participant, stored at -20°C and then shipped to Division of Environmental Health
Laboratory Sciences, National Center for Environmental Health, Centers for Disease
Control and Prevention for analysis. We included include metabolites that were assessed
for at least three NHANES series from 1999 to 2006, and that had more than 60 percent
of samples above the level of detection: MBzP, MnBP, MEHP, MEP were measured
starting in 1999 and are associated with BzBP, DBP, DEHP and DEP, respectively;

About 18,850 of the surveyed participants had missing follow-up data. However, 15,162
of these were also missing phthalate data and 1,202 of them were less than 20 years old.
Therefore, only 8 were eligible for our study, and later excluded.
1
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MiBP, MCPP, MEHHP, MEOHP and were measured starting in 2001 and are associated
with DBP, DnOP, DEHP, and DEHP, respectively. In the 1999-2000 series, the MnBP
and MiBP metabolites were not differentiated, so these measurements were combined in
subsequent series for consistency. Samples below the LOD were assigned the value of
the LOD divided by the square root of two by the laboratory conducting the analyses.
Each value was natural log transformed, and adjusted for urine dilution by dividing by
creatinine concentration.
Validation of Urinary Phthalate Metabolite Assessment
Due to decisions made by NHANES, two different methods were used to assess
phthalate concentration. From 1999 to 2002, urine was analyzed using high-pressure,
liquid chromatography tandem mass spectrometry (HPLC-MS/MS). From 2003 to 2006,
phthalate metabolites were analyzed using high performance liquid chromatographyelectrospray ionization-tandem mass spectrometry (HPLC-ESI-MS/MS). The precision
of this method was evaluated by repeated measures of quality control pools over time and
CVs were provided (Table 1).19-22 Urinary creatinine was also measured in each
participant and used to adjust for urinary dilution.
Cancer Mortality Assessment
NHANES participants were linked with mortality data through December 31,
2011 by the National Center for Health Statistics (NCHS). Participants were matched to
death certificates, National Death Index (NDI) records, SSA records, and Centers for
Medicare and Medicaid Services, and then cause of death data was ascertained from the
NDI and death certificates. Matches were determined using 12 matching variables and a
probabilistic algorithm.18 Cause of death was recoded into 10 general categories for this
9

dataset. The code “002”, any malignant neoplasm, was used for this analysis. Although
we do not have site-specific cancer data, based on previous mortality data available
through 2010, the most common cancers contributing to mortality were trachea, bronchus
and lung cancer; colon, rectum and anus cancer; and non-Hodgkin’s lymphoma.
To take advantage of data available in NHANES, we used cancer mortality as a
proxy for cancer incidence. However, cancer mortality does not adequately capture
survivable cancers which will be missed in this analysis, while aggressive cancers will be
over-represented.
Validation of Cancer Mortality
The National Center for Health Statistics (NCHS) completed a calibration study
to verify their linkage methodology for mortality follow-up.23 They used the NHANES I
Epidemiologic Follow-up survey (conducted from 1971 to 1992), which includes
participants for whom vital status was known. A sample was submitted to the NDI for
match searches, and matches were compared with each other. Of the decedents, 96.1
percent were correctly classified as deceased and correctly matched with a death
certificate. Among non-decedents, 99.4 percent were correctly classified as alive. In total,
98.5 percent of NHEFS respondents were correctly classified.
The NDI has documented cause of death data since 1979, and is the accepted
source for mortality data for large studies. A validation study of the NDI cause of death
data compared NDI underlying cause of death to the cause of death assigned by two
nosologists. They provided discrepancy rates using the NCHS code as the reference. The
discrepancy rate for all causes of death combined was four percent for NDI Plus codes
and six percent to seven percent for the study nosologists' original codes. The
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discrepancy rate for specific cancer sites was one percent for NDI Plus codes and three
percent for the final study codes.24 Cancer mortality was assessed as a dichotomous
variable.
Covariate Assessment
We considered as possible covariates demographic, lifestyle, and health factors
available from data obtained during the demographic or household section of the
NHANES questionnaire. Age at home visit, family poverty-income ratio (PIR), BMI, and
age at menarche, were assessed as continuous variables. Categorical variables included:
race (Mexican American, other Hispanic, Non-hispanic White, Non-hispanic Black, other
race/multi-race), gender (male, female), education (less than high school, high school
graduate or GED, some college or AA degree, college graduate or above), country of
birth (born in the US, born in Mexico, or born elsewhere), and marital status
(married/living with partner, never married, widowed/divorced/separated), smoking
status (smoker, non-smoker), menopausal status (pre- or post- menopausal), alcohol
intake (none, light, moderate, heavy).
Smoking status (dichotomous) was ascertained using the question “smoked at
least 100 cigarettes in lifetime?” to reduce missing data. For the last 2 series, subjects
were considered postmenopausal if the answer to the question “what is the reason that
you have not had regular periods in past 12 months?” was “menopause/hysterectomy.”
For the first 2 series they were considered postmenopausal if their answer this question
was “going-gone through menopause or their answer to “have you had a hysterectomy?”
was yes. Alcohol intake was coded as light for 1-2 drinks per day, moderate for 3-4
drinks per day, and heavy for more than 4 drinks per day. These were been identified
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based existing literature on risk factors for cancer mortality and possible association with
phthalate exposure (Table 2).
Data Analysis
Each phthalate metabolite was standardized by urinary creatinine levels to
account for urinary dilution, and natural log transformed. We calculated Pearson
correlation coefficients were calculated for continuous variables and anova for
categorical variables to assess crude correlations between each phthalate metabolite and
covariates.
Multivariable Cox proportional hazards regression was used to model the
association between urinary creatinine-adjusted phthalate metabolite concentrations
(continuously and in quartiles) and cancer mortality. Person-time was measured in
months starting from MEC exam. Participants were right censored at of time of death
from non-cancer cause or administrative censoring in December 2011.
Two models were considered for each metabolite, each stratified by sex: model 1
was adjusted for age, and model 2 was a multivariate analysis adjusted for age, BMI,
PIR, race, smoking, education, country of birth, marital status and alcohol intake. In the
female strata, model 2 was also adjusted for menopausal status and parity. Risk factors
for cancer are abundant, and vary greatly between cancer sites. When choosing
covariates, we took into account common risk factors for most prevalent cancers (cancers
of the colon, breast and lung),2 literature on phthalates, and results from our bivariate
analyses.
For all statistical analyses, SAS 9.3 was used.
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CHAPTER 3
RESULTS
Our study population was approximately 51% male and 49% female. The average
age at entry was 48 years for men and 50 years for women and about 49% were nonHispanic White, 22% were Mexican American, and 20% were Black. About 30% had
less than a high school education, and 20% of men were college graduates for more,
while 17% of women were college graduates. Among women, 65% were postmenopausal (Table 3). Mortality follow-up yielded 132 cancer deaths, 81 among men and
51 among women (Table 4).
Metabolites MBzP, MEHP, and MEP were measured in 2,654 males and 2,511
females; metabolites MCPP, MEHHP, MEOHP and MnBP were measured in 2,042
males and 1,896 females. In general, women had higher concentrations than men, with
the biggest difference in mean for MEP (males: 3.86 ug/mg, females: 4.37 ug/mg). Males
had a slightly higher mean concentration of MBzP, but larger standard deviation (SD)
(males: 0.17 ug/mg, SD: 2.14; females: 0.15 ug/mg; SD: 0.25 ug/mg) (Table 5).
Bivariate analyses showed that age was statistically significantly associated with
most phthalate metabolites for men and women. Race was significantly associated with
MEHP, MnBP, MEHHP, MEOHP, and MCPP in men, and with MBZP, MnBP and
MCPP in women, with Hispanics having the highest levels overall. Participants who were
never married had higher concentrations than married or divorced/widowed participants,
and marital status was associated with every metabolite except MEHP and MEOHP in
men, and MEHP and MnBP in women. Among women, parity was not associated with
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any metabolite, while premenopausal women had overall higher concentrations (Table 6,
6a, 7, 7a).
Due to missing data, Cox proportional hazard regressions in men included 2,359
subjects and 59 events for MEHP, MBZP and MnBP, and 1,886 participants and 43
events for MEHHP, MEOHP, and MCPP; and 2358 participants and 59 events for MEP.
Results of the age-adjusted analysis of continuous metabolites were mostly null with
hazard ratios ranging from 0.87 to 1.29. The multivariate analysis of continuous
metabolites, adjusted for age, BMI, PIR, race, smoking, education, place of birth, marital
status, and alcohol intake, yielded hazard ratios ranging from 0.90 to 1.26, with
confidence intervals including 1. The quartile analysis yielded similar results, with pvalues for trend much large than 0.05, with the exception of MEP, which had reducing
risk estimates with higher exposure, and a p-value of 0.06.
In women, Cox proportional hazard regressions results included 2,025 subjects
and 38 events for MEHP, MBZP and MnBP; 1,576 participants and 26 events for
MEHHP, MEOHP, and MCPP; and 2,022 participants and 37 events for MEP. Results of
the age-adjusted and multivariate analyses of continuous metabolites were mostly null
with hazard ratios ranging from 0.86 to 1.07. Some quartile analyses were suggestive of
increased risks with exposure, but the trends were not approaching significance (lowest
p-trend=0.12).
Results for a fully adjusted Cox proportional hazard regression for men and
women combined did not yield meaningfully different results (not shown).
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CHAPTER 4
DISCUSSION
We found no evidence of an association between urinary phthalate metabolites
and all-cancer mortality. Results for multivariate Cox proportional hazard regressions
were null, as were analysis of exposure in quartiles. As expected, we observed
differences in exposure between men and women, races and age, and between individual
phthalates.
Overall, previous literature is limited to case-control studies from occupational
settings that lack individual exposure assessment or exposure to specific compounds. The
single study that does have results for individual compounds, Lopez Carillo et al.16
reported increased odds of breast cancer for DEP metabolites (MEP) and DEHP
metabolites (MEHP, MEHHP, MEOHP) protective effects for BzBP metabolites (MBzP)
and DnOP metabolites (MCPP). We were unable to reproduce these results, and found
that in men, MBzP actually had the highest hazard ratio.
This study has several strengths. We used a cohort design with individual
exposure assessment and specific phthalate compounds with mortality follow-up to
conduct a time-to-event analysis which allowed us to take into account person-time for
the entire cohort. Our data for exposure, outcome and covariates was reliable, and
residual confounding is unlikely due to measurement error. One possible exception is
confounding due to unmeasured medication use. We were unable to account for
medication use in our analyses, which could increase phthalate metabolite levels. 7 To
reduce the chances of including very ill individuals in our analysis, we excluded
participants who died within 1 year of baseline. Lastly, NHANES is a random selection
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of the U.S. population, so selection bias in the overall dataset was unlikely and our results
could be are broadly generalizable.
Our study had several limitations. First, we used cancer mortality as a proxy for
cancer incidence; however, many cancers are survivable: overall, cancers have an on
average a 61.1 percent 5-year survival rate, 25 while many of the most prevalent cancers
have even higher rates. Therefore, many incident cancer cases likely went undetected in
our analysis because participants either survived or survived past end of follow-up.
Additionally, we could not assess site-specific cancer mortality, and missed the
opportunity to analyze cancers likely to be associated with phthalate exposure (hormonerelated cancers).
Secondly, phthalate exposure was assessed through spot urine samples, collected
at different times of the day for each participant. Phthalates are quickly metabolized in
the body, so a single urine sample will only reflect recent (<1 day) exposures. We are
unsure if a single urine sample is representative of a participant’s current actual phthalate
exposure, and what the likelihood is that that sample can represent longer term phthalate
exposures. In study among men of reproductive age, the day-to-day variance ranged
from 27.2% to 58.1%, 30-day cycle variances ranged from 1.5% to 16.3%, so the authors
concluded that day-to-day variance accounts for most of the variance within 30 days. 26
There is substantial variance in phthalate exposure that will not be captured by a single
urine sample and limits the ability of our samples to adequately estimate true exposures.
The authors also assessed the predictability of a single spot urine sample in
relation to 3-month average in tertiles. They reported sensitivities of 0.56 (MEHP), 0.63
(MBzP), 0.63 (MEP), and 0.67 (MBP).26 These are very modest sensitivities, and
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suggest that only 55-70 percent of samples were correctly classified into tertiles, so our
quartile analyses only slightly increase the accuracy of the exposure assessment.
Misclassification of exposure is likely, especially if each sample is intended to
estimate long-term exposures. This is a moderate non-differential misclassification of
exposure that will affect subjects regardless of outcome and bias the results toward the
null. In general, ability of a spot sample to predict average exposure varies by metabolite;
MEP and MBP are more representative, while MEHP, MEHHP, DEHP, are less
representative. 26, 27
Additional misclassification of exposure may persist due to urine concentration,
despite adjusting for creatinine. Creatinine adjustment is not appropriate for compounds
secreted through tubular secretion, which is suggested to be the case for phthalates, and
creatinine varies by factors such as age, BMI, exercise, and diet. Alternative methods
used are specific gravity and urinary osmolality. 26, 27 However, creatinine is what is
recommended in the NHANES dataset.
Another related concern is the temporal relationship between exposure and
cancer. Our study had between 5 and 11 years of follow-up on each participant. Since
cancers tend to have long latency periods, it is likely that a longer follow-up period would
capture more events. Additionally, we also did not take into account periods of
sensitivity; exposure in utero, during puberty or during childhood which could have a
larger effect on risk of cancer than exposure in other times of life. Lastly, this analysis is
likely underpowered to detect effects. The sample size was small after exclusions, and
events were lost in the regressions due to missing data in covariates.
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CHAPTER 5
CONCLUSION
We did not observe associations between all-cancer mortality and phthalate
metabolites (MBzP, MCPP, MEHHP, MEHP, MEOHP, MEP, MnBP) in age-adjusted or
multivariate Cox proportional hazard regressions, stratified by gender. Our study was
limited by power, mortality data instead of cancer incidence data, and misclassification of
exposure. However, it contributed longitudinal data with individual exposure assessment
to the existing literature on potential carcinogenicity of phthalates. Our study was
inconclusive, and warrants additional epidemiological, as well as toxicological, research
on the subject. We were unable to assess site-specific cancers, which would be essential
for further research. We also do not know how much our results were affected by
confounding due to exposure to medical devices or if our exposure assessment was
adequately precise. It is also possible that our study missed the window of sensitivity for
this exposure-outcome mechanism. Given the high percentage of Americans exposed to
phthalates on a daily basis, further research on the health implications of these substances
is increasingly important.
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Table 1: Sources of exposure, metabolites and analytical data for assessed phthalates
Parent
Compound

Sources of Exposurea

Metabolite

Series

CV (9900)b

CV (0102)c

CV (0304)d

CV (05-06)e

Benzylbutyl
phthalate (BzBP)

Floorings, paints, carpet backings,
adhesives, wood finishers, wallpaper,
PVC products

Mono-benzyl Phthalate
(MBzP)

19992006

9.6-12.8%

5.4-14.2%

6.3-6.4%

6.8-8.9%

Di-butyl phthalate
(DBP)

Deodorants, perfumes, personal care
products, aftershave, cosmetics,
pharmaceutical/herbal coating,
chemiluminescent glow sticks

Mono-n-butyl Phthalate
(MnBP)

19992006

7.2-22.1%

4.0-17.2%

7-7.4%

7.5-17.4%

Mono-isobutyl Phthalate
(MiBP)

20012006

7.2-8.3%

5.8-8.6%

7.3-13.2%

PVC containing medical tubing, medical
devices, food packaging, indoor air,
plastic toys, tablecloths, floor tiles,
furniture upholstery, shower curtains,
garden hoses, rainwear, baby pants, dolls,
shoes, automobile upholstery and tops,
and sheathing for wire and cable

Mono-(2-ethyl)-hexyl Phthalate
(MEHP)

19992006

8.6-15.8%

7.6-10.5%

6.3-12.0%

20012006

8.6-15.8%

6.7-8.4%

3.8-5.7%

20012006

4.8-6.0%

6.6-9.6%

3.3-4.4%

4.7-10.6%

5.1-6.0%

2.9-5.2%

4.1-4.3%

10.912.3%

14.0-15.5%

Di 2-ethylhexyl
phthalate (DEHP)

Mono-(2-ethyl-5hydroxyhexyl) Phthalate
(MEHHP)
Mono-(2-ethyl-5-oxohexyl)
Phthalate (MEOHP)

Diethyl phthalate
(DEP)

Deoderants, perfumes, personal care
products, aftershave, cosmetics,
pharmaceutical/herbal coating,
insecticide

Mono-ethyl Phthalate (MEP)

19992006

Di-n-octyl
phthalate (DnOP)

Medical tubing and blood storage bags,
wire and cables, carpetback coating, floor
tile, and adhesives, cosmetics and
pesticides

Mono-(3-carboxypropyl)
phthalate (MCPP)

20012006

10.5%18.2%

4.9-10.0%

a

Adapted from: Sathyanarayana S. Phthalates and Children's Health. Curr Probl Pediatr Adolesc Health Care 2008;34 49.
CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 1999-2000.
http://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/PHPYPA_met_phthalates.pdf . 2010. 3-29-2015.
c
CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2001-2002.
http://www.cdc.gov/nchs/data/nhanes/nhanes_01_02/PHPYPA_b_met_phthalates.pdf . 2010. 3-29-2015.
d
CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2003-2004.
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l24ph_c_met.pdf. 2013. 3-29-2015.
b

e CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2005-2006.
http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/PHTHTE_D_met.pdf. 2013. 3-29-2015.
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Table 2: Number and percent in final study sample, NHANES 1999-2006
Original Study Sample (adults eligible for follow up and
phthalate data)

6059

%

8

0.1%

67

1.1%

Ever diagnosed with cancer (except non-melanoma skin)

434

7.2%

Pregnant at time of MEC

378

6.2%

5205

86%

Incomplete follow up
Died within 12 months of baseline

Final Sample Size
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Table 3: Distribution of covariates, NHANES 1999-2006
Age (years)
BMI (kg/m2)
Ratio of family income to poverty
Race
Mexican American
Other hispanic
Non-Hispanic White
Non-Hispanic Black
Other Race /multi-race
Smoking
Smoked > 100 cigarettes in
lifetime
Smoked< 100 cigarettes in
lifetime
Education level
Less than high school
High school grad/GED or
Equivalent
Some college or AA degree
College Graduate or above
Born in US or abroad
Born in US
Born in Mexico
Born elsewhere
Marital status
Married /living with partner
Never married
Widowed, divorced, separated
Menopausal status
Premenopausal
Post menopausal
Parity
Nulliparous
1 live birth
More than 1 live birth
Alcohol intake
None
Light (1-2 drinks/day)
Moderate (3-4 drinks/day)
Heavy (>4 drinks/day)

Males (n=2669; 51%)
M
SD
missing
48.61
17.7
0
28.16
5.7
56
2.73
1.6
181
N
%
missing
0
595
22.3
115
4.3
1327
49.7
545
20.4
87
3.3
1

Females (n=2536, 49%)
M
SD
missing
50.05
18.1
0
28.85
7.1
44
2.62
1.6
209
N
%
missing
0
563
22.2
113
4.5
1221
48.2
546
21.5
93
3.7
3

1518

56.9

976

38.5

1150

43.1

1557

61.5

840

31.5

777

30.7

626

23.5

581

23.0

665
533

25.0
20.0

727
447

28.7
17.7

2001
382
284

75.0
14.3
10.7

1986
324
224

78.4
12.8
8.8

1764
448
390

67.8
17.2
15.0

1384
351
740

55.9
14.2
29.9

-----

-----

-----

1192
1242

49.0
51.0

-------

-------

------0

255
327
1602

11.7
15.0
73.4

337
1435
457
440

12.6
53.8
17.1
16.5

780
1420
237
99

30.8
56.0
9.4
3.9

5

4

2

2

67

61

102

352
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Table 4: Distribution of cancer mortality, NHANES 1999-2006 with
follow-up through 2011
All
Cancer mortality

Males

Females

132 81 (61%)

51 (39%)

Table 5: Distribution of creatinine adjusted, phthalate metabolite
concentration (ug/mg), NHANES 1999-2006

MBzP
MCPP
MEHHP
MEHP
MEOHP
MEP
MnBP

Mean
0.17
0.03
0.41
0.07
0.25
3.86
0.35

Males
SD
2.14
0.10
1.01
0.21
0.60
10.29
3.23

N
2654
2042
2042
2654
2042
2653
2042

Mean
0.15
0.04
0.45
0.07
0.29
4.37
0.43
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Females
SD
0.25
0.15
1.13
0.24
0.69
17.95
1.55

N
2511
1896
1896
2511
1896
2507
1896

Table 6: Distribution of creatinine adjusted, log transformed phthalate metabolite concentration (ug/mg) and
coefficients, males, NHANES 1999-2006
MEHP
Coefficient
(p-value)

MEP
Coefficient
(p-value)

MBzP
Coefficient
(p-value)
-0.04
(0.04)

MnBP
Coefficient
(p-value)

MEHHP
Coefficient
(p-value)

MEOPH
Coefficient
(p-value)

MCPP
Coefficient
(p-value)

Age (years)

-0.13 (<.01)

0.02 (0.32)

0.05(0.04)

-0.05(0.03)

-0.02(0.32)

0.11(<.001)

Body Mass Index
(kg/m2)

-0.02 (0.33)

0.05(0.02)

0.01 (0.62)

-0.02(0.28)

0.07 (<0.01)

0.07(<0.00)

0.01(0.66)

Family PIR

0.03 (0.17)

-0.03(0.15)

-0.12
(<0.01)

-0.12(<0.01)

0.07 (<0.01)

0.08(<0.01)

0.00(0.83)

MEHP

MEP

MBzP

MnBP

MEHHP

MEOHP

MCPP

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

0.03 (3.22)

1.40 (4.22)

0.06 (2.69)

0.19 (2.23)

0.15 (2.97)

0.10 (2.8)

0.02 (2.34)

0.04 (3.9)

1.60 (4.35)

0.08 (2.64)

0.21 (1.9)

0.20 (3.00)

0.12 (2.86)

0.02 (2.34)

0.03 (3.35)

0.98 (4.39)

0.07 (2.77)

0.18 (2.25)

0.18 (3.22)

0.12 (3.10)

0.02 (2.39)

0.03 (3.67)

1.48 (4.06)

0.07 (2.77)

0.19 (2.20)

0.17 (3.22)

0.11 (3.06)

0.01 (2.56)

0.02 (2.89)

0.72 (3.82)

0.06 (2.97)

0.21 (2.89)

0.14 (2.92)

0.08 (2.80)

0.01 (2.53)

0.01

0.08

<0.01

0.12

0.01

0.01

<0.01

0.03 (3.39)
0.03 (3.42)

1.21 (4.62)
1.12 (3.94)

0.07 (2.80)
0.07 (2.69)

0.18 (2.32)
0.17 (2.14)

0.17 (3.22)
0.18 (3.03)

0.11 (3.10)
0.11 (2.92)

0.02 (2.51)
0.02 (2.32)

0.50

0.09

0.20

<0.01

0.13

0.15

0.07

Race
Mexican
American
Other hispanic
Non-Hispanic
White
Non-Hispanic
Black
Other Race
/multi-race
ANOVA p-value
Smoking
Smoker
Non-smoker
ANOVA p-value
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Table 6a: Distribution of creatinine adjusted, log transformed phthalate metabolite concentration (ug/mg) and coefficients,
males, NHANES 1999-2006, continued

Education level
Less than high school
High school grad or
equivalent
Some college or AA
College graduate or above
ANOVA p-value
Born in US or abroad
Born in US
Born in Mexico
Born elsewhere
ANOVA p-value
Marital status
Married /living with
partner
Never married
Widowed, divorced,
separated
ANOVA p-value
Alcohol intake
None
Light (1-2 drinks/day)
Moderate (3-4 drinks/day)
Heavy (>4 drinks/day)
ANOVA p-value

MEHP
Mean (SD)

MEP
Mean (SD)

MBzP
Mean (SD)

MnBP
Mean (SD)

MEHHP
Mean (SD)

MEOHP
Mean (SD)

MCPP
Mean (SD)

0.02 (3.13)

1.32 (4.66)

0.07 (2.89)

0.20 (2.29)

0.14 (2.92)

0.09 (2.80)

0.02 (2.44)

0.02 (3.53)

1.25 (4.18)

0.07 (2.56)

0.18 (2.18)

0.18 (3.10)

0.11 (3.03)

0.02 (2.44)

0.03 (3.67)
0.03 (3.39)
0.03

1.12 (4.18)
0.95 (4.01)
<0.01

0.07 (2.75)
0.06 (2.77)
<0.01

0.18 (2.25)
0.17 (2.18)
<0.01

0.19 (3.25)
0.19 (3.29)
<0.01

0.12 (3.10)
0.12 (3.16)
<0.01

0.02 (2.51)
0.02 (2.36)
0.38

0.03 (3.46)
0.03 (3.10)
0.03 (3.46)
0.10

1.11 (4.31)
1.54 (4.14)
1.2 (4.35)
<0.01

0.07 (2.75)
0.06 (2.72)
0.06 (2.80)
<0.01

0.18 (2.23)
0.19 (2.29)
0.23 (2.23)
<0.01

0.18 (3.22)
0.15 (2.92)
0.16 (2.97)
0.01

0.11 (3.10)
0.09 (2.75)
0.1 (2.80)
0.01

0.02 (2.48)
0.02 (2.16)
0.02 (2.53)
0.22

0.03 (3.32)

1.17 (4.31)

0.06 (2.75)

0.18 (2.23)

0.17 (3.13)

0.11 (2.97)

0.02 (2.41)

0.03 (3.82)

1.08 (3.86)

0.07 (2.80)

0.18 (2.27)

0.18 (3.46)

0.11 (3.29)

0.02 (2.56)

0.02 (3.29)

1.28 (4.9)

0.08 (2.69)

0.20 (2.29)

0.17 (2.94)

0.11 (2.92)

0.02 (2.39)

0.01

<0.01

0.24

0.11

0.98

0.97

<0.01

0.02 (3.29)
0.03 (3.35)
0.03 (3.67)
0.03 (3.42)
0.79

1.19 (4.44)
1.13 (4.39)
1.25 (3.97)
1.21 (4.39)
0.14

0.07 (2.48)
0.07 (2.80)
0.07 (2.48)
0.07 (3.13)
0.53

0.18 (2.27)
0.18 (2.23)
0.18 (2.16)
0.19 (2.39)
0.99

0.15 (2.72)
0.18 (3.03)
0.18 (3.6)
0.17 (3.35)
0.11

0.1 0(2.61)
0.11 (2.92)
0.11 (3.46)
0.10 (3.16)
0.19

0.02 (2.51)
0.02 (2.39)
0.02 (2.39)
0.02 (2.53)
0.01
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Table 7: Distribution of creatinine adjusted, log transformed phthalate metabolite concentrations (ug/mg), females, NHANES
1999-2006
Pearson coefficient
Age (years)
Body Mass Index
(kg/m2)
Family PIR
Race
Mexican American
Other hispanic
Non-Hispanic White
Non-Hispanic Black
Other Race /multi-race
ANOVA p-value
Smoking
Smoker
Non-smoker
ANOVA p-value
Menopausal status
Premenopausal
Postmenopausal
ANOVA p-value
Parity
Nulliparous
1 live birth
More than 1 live birth
ANOVA p-value

MEHP
Coefficient
(p-value)
-0.09 (<0.01)

MEP
Coefficient (pvalue)
-0.06 (0.01)

MBzP
Coefficient
(p-value)
-0.06 (0.01)

MnBP
Coefficient
(p-value)
0.00 (0.85)

MEHHP
Coefficient
(p-value)
-0.04 (0.13)

MEOPH
Coefficient
(p-value)
-0.04 (0.07)

MCPP
Coefficient
(p-value)
0.11 (<0.1)

-0.08 (<0.01)

0.04 (0.11)

0.06 (0.01)

-0.04 (0.13)

0.05 (0.04)

0.05 (0.02)

-0.02 (0.40)

0.02 (0.38)
Mean (SD)
M(SD)
0.03 (2.97)
0.03 (2.97)
0.03 (3.10)
0.03 (3.13)
0.03 (3.10)
0.82

-0.04 (0.07)
Mean (SD)
M(SD)
2.03 (3.35)
2.2 (3.49)
1.26 (3.63)
1.88 (3.56)
0.93 (4.39)
0.06

-0.16 (<0.01)
Mean (SD)
M(SD)
0.08 (2.77)
0.1 (2.41)
0.09 (2.69)
0.09 (2.69)
0.08 (2.97)
<0.01

-0.09 (<0.01)
Mean (SD)
M(SD)
0.29 (2.29)
0.39 (2.12)
0.26 (2.25)
0.28 (2.16)
0.28 (2.27)
<0.01

0.04 (0.07)
Mean (SD)
M(SD)
0.19 (2.69)
0.25 (2.51)
0.21 (2.92)
0.22 (2.94)
0.18 (3.06)
0.11

0.05 (0.05)
Mean (SD)
M(SD)
0.13 (2.56)
0.16 (2.59)
0.14 (2.86)
0.14 (2.89)
0.12 (2.86)
0.37

-0.02 (0.33)
Mean (SD)
M(SD)
0.02 (2.41)
0.03 (2.18)
0.02 (2.32)
0.02 (2.41)
0.02 (2.89)
<0.01

0.03 (2.94)
0.03 (3.13)
0.12

1.54 (3.74)
1.55 (3.6)
<0.01

0.09 (2.80)
0.08 (2.66)
<0.01

0.29 (2.29)
0.26 (2.2)
0.6

0.20 (2.66)
0.21 (3.00)
0.51

0.13 (2.64)
0.14 (2.89)
0.15

0.02 (2.41)
0.02 (2.39)
0.59

0.04 (3.29)
0.03 (2.86)
<0.01

1.68 (3.67)
1.43 (3.63)
0.10

0.09 (2.61)
0.08 (2.77)
0.79

0.28 (2.23)
0.27 (2.25)
0.01

0.22 (3.13)
0.20 (2.64)
0.01

0.15 (3.03)
0.13 (2.59)
<0.01

0.02 (2.39)
0.02 (2.41)
<0.01

0.03 (3.00)
0.03 (3.10)
0.03 (3.06)
0.55

1.45 (3.97)
1.77 (3.78)
1.52 (3.56)
0.15

0.07 (2.77)
0.08 (2.66)
0.09 (2.72)
0.35

0.26 (2.12)
0.28 (2.18)
0.28 (2.29)
0.17

0.24 (2.89)
0.21 (2.97)
0.20 (2.86)
0.16

0.16 (2.80)
0.14 (2.97)
0.13 (2.75)
0.08

0.02 (2.39)
0.02 (2.32)
0.02 (2.41)
0.21
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Table 7a: Distribution of creatinine adjusted, log transformed phthalate metabolite concentrations (ug/mg), females, NHANES
1999-2006, continued
Pearson coefficient
Education level
Less than high school
High school grad or Equivalent
Some college or AA degree
College Graduate or above
ANOVA p-value
Born in US or abroad
Born in US
Born in Mexico
Born elsewhere
ANOVA p-value
Marital status
Married /living with partner
Never married
Widowed, divorced, separated
ANOVA p-value
Alcohol intake
None
Light (1-2 drinks/day)
Moderate (3-4 drinks/day)
Heavy (>4 drinks/day)
ANOVA p-value

MEHP
Coefficient (pvalue)

MEP
Coefficient
(p-value)

MBzP
Coefficient
(p-value)

MnBP
Coefficient
(p-value)

MEHHP
Coefficient
(p-value)

MEOPH
Coefficient
(p-value)

MCPP
Coefficient
(p-value)

0.03 (3.13)
0.03 (3.00)
0.03 (3.00)
0.03 (3.16)
0.6

1.72 (3.67)
1.67 (3.56)
1.49 (3.71)
1.22 (3.53)
0.01

0.09 (2.94)
0.09 (2.53)
0.09 (2.61)
0.07 (2.69)
0.27

0.28 (2.29)
0.28 (2.20)
0.26 (2.14)
0.27 (2.39)
<0.01

0.19 (2.86)
0.21 (2.83)
0.20 (2.83)
0.23 (3.03)
0.02

0.13 (2.75)
0.14 (2.77)
0.13 (2.75)
0.15 (2.97)
0.07

0.02 (2.64)
0.02 (2.25)
0.02 (2.29)
0.02 (2.41)
0.65

0.03 (3.29)
0.03 (3.03)
0.03 (3.10)
0.34

1.48 (3.63)
2.01 (3.25)
1.65 (4.26)
<0.01

0.09 (2.72)
0.07 (2.80)
0.07 (2.46)
<0.01

0.27 (2.23)
0.28 (2.27)
0.34 (2.27)
<0.01

0.21 (2.89)
0.18 (2.92)
0.19 (2.61)
0.02

0.14 (2.83)
0.12 (2.69)
0.13 (2.56)
0.08

0.02 (2.39)
0.02 (2.44)
0.02 (2.34)
0.03

0.03 (3.13)
0.03 (3.16)
0.03 (2.92)
0.09

1.49 (3.67)
1.75 (3.32)
1.58 (3.74)
0.02

0.08 (2.75)
0.08 (2.86)
0.09 (2.59)
<0.01

0.26 (2.29)
0.28 (2.25)
0.30 (2.12)
0.14

0.20 (2.97)
0.23 (2.92)
0.21 (2.64)
0.03

0.13 (2.92)
0.15 (2.80)
0.14 (2.59)
0.02

0.02 (2.36)
0.02 (2.34)
0.02 (2.48)
<0.01

0.03 (3.00)
0.03 (3.06)
0.03 (3.22)
0.03 (3.49)
0.68

1.52 (3.39)
1.52 (3.82)
1.82 (3.42)
1.54 (4.10)
<0.01

0.09 (2.69)
0.08 (2.72)
0.10 (2.66)
0.13 (2.56)
0.17

0.26 (2.20)
0.27 (2.29)
0.31 (1.93)
0.38 (2.29)
0.01

0.18 (2.72)
0.22 (2.92)
0.21 (2.92)
0.26 (2.92)
<0.01

0.12 (2.64)
0.14 (2.86)
0.14 (2.83)
0.18 (2.89)
0.01

0.02 (2.36)
0.02 (2.36)
0.02 (2.53)
0.02 (2.75)
0.24
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Table 8. Adjusted hazard ratios and 95% confidence intervals for cancer mortality and creatinine adjusted, log
transformed urinary phthalate metabolite concentration (ug/mg), males, NHANES 1999-2006
Model 1a
95% CI LB

95% CI UB

HR

Model 2b
95% CI LB

95% CI UB

0.99
1.00
1.33
1.22
1.09
0.79

0.78
---0.69
0.60
0.50

1.24
---2.56
2.49
2.37

0.97
1.00
1.29
1.09
1.06
0.92

0.77
---0.67
0.53
0.48

1.23
---2.51
2.25
2.33

59

0.91
1.00
0.70
0.67
0.60
0.13

0.77
---0.35
0.33
0.30

1.08
---1.40
1.37
1.20

0.89
1.00
0.64
0.61
0.51
0.06

0.75
---0.32
0.30
0.25

1.06
---1.30
1.27
1.05

2359

59

1.29
1.00
1.45
2.16
1.25
0.30

1.01
---0.70
1.07
0.56

1.66
---3.02
4.38
2.80

1.27
1.00
1.30
2.23
1.13
0.38

0.98
---0.62
1.09
0.50

1.64
---2.74
4.55
2.55

1886

c

43

1.08
1.00
0.98
1.15
0.73
0.66

0.74
---0.45
0.52
0.29

1.58
---2.14
2.57
1.83

1.07
1.00
0.98
1.04
0.69
0.54

0.73
---0.44
0.46
0.27

1.56
---2.17
2.35
1.76

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

1886

c

43

0.90
1.00
0.90
0.30
0.82
0.21

0.68
---0.44
0.10
0.37

1.19
---1.86
0.88
1.84

0.92
1.00
0.97
0.32
0.82
0.23

0.70
---0.46
0.11
0.36

1.21
---2.03
0.95
1.88

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

1886

c

43

0.87
1.00
0.94
0.40
0.83
0.29

0.64
---0.45
0.15
0.37

1.17
---1.96
1.09
1.88

0.89
1.00
1.05
0.44
0.82
0.31

0.67
---0.50
0.16
0.35

1.20
---2.22
1.23
1.88

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

1886c

43

0.94
1.00
0.54
0.87
0.76
0.70

0.67
---0.22
0.40
0.34

1.32
---1.33
1.88
1.72

0.92
1.00
0.56
0.87
0.76
0.72

0.66
---0.22
0.39
0.33

1.30
---1.42
1.91
1.75

N

Events

HR

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

2359

59

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

2358

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend
Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

MEHP

MEP

MBzP

MnBP

MEHHP

MEOHP

MCPP

a

Age-adjusted Cox proportional hazard regression

b

Cox proportional hazard regression, adjusted for age, BMI, ratio of family income to poverty, race, smoking, education, diabetes status, place of birth,
C
Assessed for 3 out of 4 series
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Table 9. Adjusted hazard ratios and 95% confidence intervals for cancer mortality and creatinine adjusted, log
transformed urinary phthalate metabolite concentration (ug/mg), females, NHANES 1999-2006
N

Model 1a
95% CI LB 95% CI UB

HR

Model 2b
95% CI LB 95% CI UB

Events

HR

Continuous
2025
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

38

0.94
1.00
0.86
0.28
0.91
0.42

0.69
---0.38
0.09
0.39

1.27
---1.94
0.89
2.09

0.98
1.00
0.94
0.31
1.05
0.63

0.72
---0.41
0.10
0.44

1.34
---2.17
1.00
2.47

Continuous
2022
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

37

1.06
1.00
0.53
0.56
1.11
0.66

0.83
---0.20
0.21
0.49

1.35
---1.39
1.47
2.55

1.07
1.00
0.53
0.59
1.19
0.54

0.84
---0.20
0.22
0.50

1.37
---1.41
1.59
2.83

Continuous
2025
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

38

0.98
1.00
0.68
0.32
0.76
0.33

0.71
---0.29
0.11
0.34

1.35
---1.61
0.90
1.70

1.01
1.00
0.67
0.32
0.82
0.43

0.71
---0.28
0.11
0.36

1.42
---1.60
0.92
1.88

c

26
0.86
1.00
1.91
1.28
1.38
0.95

0.53
---0.49
0.32
0.38

1.38
---7.39
5.12
5.01

0.92
1.00
2.07
1.55
1.62
0.73

0.56
---0.53
0.38
0.44

1.50
---8.10
6.33
6.01

0.95
1.00
1.15
0.66
0.63
0.27

0.63
---0.41
0.21
0.19

1.42
---3.23
2.05
2.05

0.94
1.00
1.15
0.66
0.64
0.29

0.62
---0.40
0.21
0.19

1.42
---3.29
2.07
2.12

0.87
1.00
1.70
0.84
0.45
0.12

0.56
---0.59
0.27
0.11

1.34
---4.89
2.63
1.88

0.86
1.00
1.60
0.84
0.42
0.12

0.56
---0.54
0.26
0.10

1.33
---4.77
2.70
1.80

0.91
1.00
0.29
1.52
0.53
0.79

0.56
---0.06
0.54
0.16

1.45
---1.50
4.29
1.75

0.90
1.00
0.28
1.50
0.52
0.84

0.55
---0.05
0.52
0.15

1.49
---1.45
4.34
1.80

MEHP

MEP

MBzP

MnBP

1576
Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

1576c

MEHHP

26

Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend
MEOHP
Continuous
1576c
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend

26

1576c

26

MCPP
Continuous
1st quartile (referent)
2nd quartile
3rd quartile
4th quartile
p-trend
a

Age-adjusted Cox proportional hazard regression
Cox proportional hazard regression, adjusted for age, BMI, ratio of family income to poverty, race, smoking, education,place of birth,

b
c

Assessed for 3 out of 4 series
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